Association between post-balloon angioplasty dissection and primary patency in complex femoropopliteal artery disease: 2-year clinical outcomes of the AcoArt I trial

J Int Med Res. 2021 Apr;49(4):3000605211006546. doi: 10.1177/03000605211006546.

Abstract

Objective: To assess the association between post-balloon angioplasty dissection and the mid-term results of the AcoArt I trial evaluating complex femoropopliteal artery disease.

Methods: The outcome data for 144 patients from the AcoArt 1 trial were reanalysed. These patients were randomly divided into percutaneous transluminal angioplasty (PTA) and drug-coated balloons (DCB) groups. The primary endpoint was the primary patency (PP) rate and clinically-driven target lesion revascularisation at 24 months.

Results: After 24 months of follow-up, the PP rate of dissection cases in the PTA group was lower vs non-dissection cases. In patients receiving a bailout stent for dissection, the PP rate in the PTA group was lower vs the DCB group. Cox regression analysis showed that dissection decreased the PP rate; mild dissection reduced the PP rate as follows: 52%, PTA group and 19%, DCB group. With severe dissection, the PP rate reduction was as follows: 75%, PTA group and 73%, DCB group.

Conclusions: The mid-term follow-up showed that post-balloon angioplasty dissection reduced the PP rate in the PTA group but not in the DCB group. Additionally, in patients receiving a bailout stent for dissection, the DCB group had a better PP rate than the PTA group.

Keywords: Balloon angioplasty; dissection; drug-coated balloon; femoropopliteal artery disease; percutaneous transluminal angioplasty; primary patency.

Publication types

  • Clinical Trial

MeSH terms

  • Angioplasty, Balloon*
  • Coated Materials, Biocompatible
  • Dissection
  • Humans
  • Paclitaxel
  • Peripheral Arterial Disease* / surgery
  • Popliteal Artery / diagnostic imaging
  • Popliteal Artery / surgery
  • Prospective Studies
  • Time Factors
  • Treatment Outcome

Substances

  • Coated Materials, Biocompatible
  • Paclitaxel